Skip to main content

Advertisement

Table 1 Baseline characteristics of subjects in the placebo and tiotropium arms of the UPLIFT trial included in the analysis of time trends in bronchodilator responses over the course of the trial

From: Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD

Characteristic Placebo (N = 2463) Tiotropium (N = 2579)
Age, yrs, mean (SD) 64.2 (8.39) 64.3 (8.39)
>65 yrs, N (%) 1158 (47.0%) 1223 (47.4%)
≤65 yrs, N (%) 1305 (53.0%) 1356 (52.6%)
Gender, male, N (%) 1852 (75.2%) 1965 (76.2%)
Pre-bronchodilator FEV1, L, mean (SD) 1.12 (0.40) 1.11 (0.40)
Pre-bronchodilator FEV1, % predicted, mean (SD) 39.9 (11. 8) 39.8 (11.9)
Post-bronchodilator FEV1, L, mean (SD) 1.35 (0.44) 1.34 (0.43)
Post-bronchodilator FEV1, % predicted, mean (SD) 48.2 (12.4) 48.1 (12.5)
Pre-bronchodilator FVC, L, mean (SD) 2.66 (0.83) 2.64 (0.80)
Pre-bronchodilator FVC, % predicted, mean (SD) 75.4 (18.0) 74.8 (17.9)
Post-bronchodilator FVC, L, mean (SD) 3.13 (0.90) 3.11 (0.86)
Post-bronchodilator FVC, % predicted, mean (SD) 88.7 (18.7) 88.2 (18.5)
Pre-bronchodilator FEV1/FVC ratio, %, mean (SD) 42.5 (10.3) 42.7 (10.4)
Post-bronchodilator FEV1/FVC ratio, %, mean (SD) 43.8 (10.5) 43.9 (10.7)
Smoking status   
Sustained ex-smoker, N (%) 1471 (59.7%) 1502 (58.2%)
Intermittent smoker, N (%) 679 (27.6%) 761 (29.5%)
Continuing smoker, N (%) 313 (12.7%) 316 (12.3%)
Pack-yrs smoking, mean (SD) 48.0 (27.9) 49.0 (28.0)
GOLD grade of airflow obstruction   
Grade I/II, N (%) 1179 (48.6%) 1226 (48.3%)
Grade III, N (%) 1059 (43.6%) 1118 (44.0%)
Grade IV, N (%) 189 (7.79%) 197 (7.75%)
Use of Inhaled Corticosteroids at baseline   
Yes 1506 (61.1%) 1581 (61.3%)
No 957 (38.9%) 998 (38.7%)
SGRQ total scores, mean (SD) 45.2 (17.2) 45.0 (17.0)